The PrELUDE study is designed to look into how clinics can provide pre-exposure prophylaxis (PrEP) in NSW. For PrEP, a drug is given to HIV-negative people to prevent infection with HIV before they are actually exposed.
The drug currently being used for PrEP is called Truvada. Truvada is already used in Australia as a treatment for people who have HIV, but is not yet licensed for use as PrEP. (The US approved Truvada for PrEP use in 2012.)
Participants in the PrELUDE Study will take PrEP for at least 30 days and up to 12 months. Participants will also attend a follow-up visit three months after stopping PrEP, and will take a survey six months after stopping PrEP.
Conducted by investigators from the Kirby Institute and UNSW Australia, PrELUDE aims to study whether people in NSW find PrEP easy and agreeable to take every day, why they take it, what it’s like to take it, and whether it changes how the participants have sex.
PrELUDE will also study how easy it is for doctors to use it with their patients, and what resources are necessary to make PrEP available in NSW. The study is being conducted out of participating health services in the Sydney area, as well as other parts of NSW.
In order to qualify for the PrELUDE Study you must:
- Be at least 18 years old
- Be HIV negative
- Visit a participating clinic if you are at high or ongoing risk of getting HIV through sex
- Live in NSW, or visit NSW enough to attend all of the follow-up visits
- Be willing to take a computer-based survey about your attitudes, behaviours and lifestyle throughout the study
- Meet other study criteria assessed by study staff at a participating clinic
For further details and to enrol click here.